3SBio Signs Deal For Isotechnika's Transplant/Immune System Drug Voclosporin
This article was originally published in The Pink Sheet Daily
The deal was announced less than three weeks after U.S. FDA requested an additional Phase III trial for an oral voclosporin used in uveitis therapy.
You may also be interested in...
"Several outstanding issues" forced FDA to cancel the meeting, the agency said.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.